Evidence map›Paper›PMID 29310717›Full record

ArticleGenome medicine2018

Characterization of glycosylphosphatidylinositol biosynthesis defects by clinical features, flow cytometry, and automated image analysis.

Alexej Knaus, Jean Tori Pantel, Manuela Pendziwiat, Nurulhuda Hajjir, Max Zhao, Tzung-Chien Hsieh, Max Schubach, Yaron Gurovich, Nicole Fleischer, Marten Jäger and 26 more

Abstract read
In one paragraph

Article in Genome medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Observational
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Alexej KnausInstitut für Medizinische Genetik und Humangenetik, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany.
Jean Tori PantelInstitut für Medizinische Genetik und Humangenetik, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany.
Manuela PendziwiatDepartment of Neuropediatrics, University Medical Center Schleswig Holstein, 24105, Kiel, Germany.
Nurulhuda HajjirInstitut für Medizinische Genetik und Humangenetik, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany.
Max ZhaoInstitut für Medizinische Genetik und Humangenetik, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany.
Tzung-Chien HsiehInstitut für Medizinische Genetik und Humangenetik, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany.
Max SchubachInstitut für Medizinische Genetik und Humangenetik, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany.
Yaron GurovichFDNA Inc., Boston, MA, USA.
Nicole FleischerFDNA Inc., Boston, MA, USA.
Marten JägerInstitut für Medizinische Genetik und Humangenetik, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany.
Sebastian KöhlerInstitut für Medizinische Genetik und Humangenetik, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany.
Hiltrud MuhleDepartment of Neuropediatrics, University Medical Center Schleswig Holstein, 24105, Kiel, Germany.
Christian KorffUnité de Neuropédiatrie, Université de Genève, CH-1211, Genève, Switzerland.
Rikke S MøllerDanish Epilepsy Centre, DK-4293, Dianalund, Denmark.
Allan BayatDepartment of Pediatrics, University Hospital of Hvidovre, 2650, Hvicovre, Denmark.
Patrick CalvasService de Génétique Médicale, Hôpital Purpan, CHU, 31059, Toulouse, France.
Nicolas ChassaingService de Génétique Médicale, Hôpital Purpan, CHU, 31059, Toulouse, France.
Hannah WarrenGreenwood Genetic Center, SC29646, Greenwood, USA.
Steven SkinnerGreenwood Genetic Center, SC29646, Greenwood, USA.
Raymond LouieGreenwood Genetic Center, SC29646, Greenwood, USA.
Christina EversGenetische Poliklinik, Universitätsklinik Heidelberg, 69120, Heidelberg, Germany.
Marc BohnSt. Bernward Krankenhaus, 31134, Hildesheim, Germany.
Hans-Jürgen ChristenKinderkrankenhaus auf der Bult, Hannoversche Kinderheilanstalt, 30173, Hannover, Germany.
Myrthe van den BornDepartment for Clinical Genetics, Erasmus MC, 3000, Rotterdam, Netherlands.
Ewa ObersztynInstitute of Mother and Child Department of Molecular Genetics, 01-211, Warsaw, Poland.
Agnieszka CharzewskaInstitute of Mother and Child Department of Molecular Genetics, 01-211, Warsaw, Poland.
Milda EndzinieneNeurology Department, Lithuanian University of Health Sciences, 50009, Kaunas, Lithuania.
Fanny KortümInstitute of Human Genetics, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.
Natasha BrownVictorian Clinical Genetics Services, Royal Children's Hospital, MCRI, Parkville, Australia.
Peter N RobinsonThe Jackson Laboratory for Genomic Medicine, 06032, Farmington, USA.
Helenius J SchelhaasDepartement of Neurology, Academic Center for Epileptology, 5590, Heeze, The Netherlands.
Yvonne WeberDepartment of Neurology and Epileptology and Hertie Institute for Clinical Brain Research, University Tübingen, 72076, Tübingen, Germany.
Ingo HelbigInstitute for Genomic Statistics and Bioinformatics, University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, 53127, Bonn, Germany.
Stefan MundlosInstitut für Medizinische Genetik und Humangenetik, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany.
Denise HornInstitut für Medizinische Genetik und Humangenetik, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany. denise.horn@charite.de.
Peter M KrawitzInstitut für Medizinische Genetik und Humangenetik, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany. pkrawitz@uni-bonn.de.

Funding

Bundesministerium für Bildung und Forschung 01EC1402BDeutsche Forschungsgemeinschaft HE5415/6-1Deutsche Forschungsgemeinschaft WE4896/3-1
6 · The paper itself

Abstract

backgroundGlycosylphosphatidylinositol biosynthesis defects (GPIBDs) cause a group of phenotypically overlapping recessive syndromes with intellectual disability, for which pathogenic mutations have been described in 16 genes of the corresponding molecular pathway. An elevated serum activity of alkaline phosphatase (AP), a GPI-linked enzyme, has been used to assign GPIBDs to the phenotypic series of hyperphosphatasia with mental retardation syndrome (HPMRS) and to distinguish them from another subset of GPIBDs, termed multiple congenital anomalies hypotonia seizures syndrome (MCAHS). However, the increasing number of individuals with a GPIBD shows that hyperphosphatasia is a variable feature that is not ideal for a clinical classification.

methodsWe studied the discriminatory power of multiple GPI-linked substrates that were assessed by flow cytometry in blood cells and fibroblasts of 39 and 14 individuals with a GPIBD, respectively. On the phenotypic level, we evaluated the frequency of occurrence of clinical symptoms and analyzed the performance of computer-assisted image analysis of the facial gestalt in 91 individuals.

resultsWe found that certain malformations such as Morbus Hirschsprung and diaphragmatic defects are more likely to be associated with particular gene defects (PIGV, PGAP3, PIGN). However, especially at the severe end of the clinical spectrum of HPMRS, there is a high phenotypic overlap with MCAHS. Elevation of AP has also been documented in some of the individuals with MCAHS, namely those with PIGA mutations. Although the impairment of GPI-linked substrates is supposed to play the key role in the pathophysiology of GPIBDs, we could not observe gene-specific profiles for flow cytometric markers or a correlation between their cell surface levels and the severity of the phenotype. In contrast, it was facial recognition software that achieved the highest accuracy in predicting the disease-causing gene in a GPIBD.

conclusionsDue to the overlapping clinical spectrum of both HPMRS and MCAHS in the majority of affected individuals, the elevation of AP and the reduced surface levels of GPI-linked markers in both groups, a common classification as GPIBDs is recommended. The effectiveness of computer-assisted gestalt analysis for the correct gene inference in a GPIBD and probably beyond is remarkable and illustrates how the information contained in human faces is pivotal in the delineation of genetic entities.

Indexed as

Image Processing, Computer-AssistedAbnormalities, MultipleAutomationBiomarkersFlow CytometryGlycosylphosphatidylinositolsHumansIntellectual DisabilityPhenotypePhosphorus Metabolism DisordersSyndromeBiomarkersGlycosylphosphatidylinositolsAnchor biosynthesis defectsAutomated image analysisGeneGPIPrediction

Identifiers

PMID29310717
PMCPMC5759841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.